Han, Y and Shen, H and Carr, BI and Wipf, P and Lazo, JS and Pan, SS
(2004)
NAD(P)H:Quinone Oxidoreductase-1-Dependent and -Independent Cytotoxicity of Potent Quinone Cdc25 Phosphatase Inhibitors.
Journal of Pharmacology and Experimental Therapeutics, 309 (1).
64 - 70.
ISSN 0022-3565
![[img]](http://d-scholarship-dev.library.pitt.edu/style/images/fileicons/text_plain.png) |
Plain Text (licence)
Available under License : See the attached license file.
Download (1kB)
|
Abstract
Cdc25 dual-specificity phosphatases coordinate cell cycle progression and cellular signaling. Consequently, Cdc25 inhibitors represent potential anticancer agents. We evaluated >10,000 compounds for inhibition of human Cdc25 phosphatases and identified many potent and selective inhibitors, which all contained a quinone. Bioreductive enzymes frequently detoxify or activate quinones. Therefore, we evaluated the effect of NAD(P)H:quinone oxidoreductase-1 (NQO1) and reductase-rich microsomes on the activity of three quinone-containing Cdc25 inhibitors: 2-(2-hydroxyethylsulfanyl)-3-methyl-1,4-naphthoquinone (Cpd 5, compound 5; NSC 672121), 2,3-bis-(2-hydroxyethylsulfanyl)-1,4-naphthoquinone (NSC 95397), and 6-chloro-7-(2-morpholin-4-ylethylamino)quinoline-5,8-dione (NSC 663284). Each inhibitor was reduced by human NQO1 (Km of 0.3-0.5 μM) but none by microsomes. Compounds were evaluated with six cancer cell lines containing different amounts of NQO1: HT-29 (1056 nmol/mg/ min), HCT116 (660 nmol/mg/min), sublines HCT116-R30A (28 nmol/mg/min) and HCT-116R30A/NQ5 (934 nmol/mg/min), MDA-MB-231/Q2 (null NQO1), and subline MDA-MB-231/Q6 (124 nmol/mg/min) but containing similar amounts of microsomal cytochrome P450 reductase and cytochrome b5 reductase. Growth inhibition and G2/M arrest by Cpd 5 was proportional to NQO1 levels, requiring 4- to 5-fold more Cpd 5 to inhibit HCT-116 or HCT-116R30A/NQ5 compared with HCT-116R30A. In contrast, in all tested cell lines irrespective of NQO1 level, growth inhibition and G2/M arrest by NSC 95375 and NSC 663284 were similar (average IC50 of 1.3 ± 0.3 and 2.6 ± 0.4 μM, respectively). NSC 95375 and NSC 663284 also caused similar Cdk1 hyperphosphorylation, indicating similar Cdc25 inhibition. However, lower Cpd 5 concentrations were needed to produce Cdk1 hyperphosphorylation in sublines with minimal NQO1. Thus, NQO1 detoxified Cpd 5, probably by reducing it to a less active hydroquinone, whereas NSC 95397- and NSC 663284-generated cytotoxicity was unaffected by NQO1.
Share
| Citation/Export: |
|
| Social Networking: |
|
Details
| Item Type: |
Article
|
| Status: |
Published |
| Creators/Authors: |
|
| Date: |
1 April 2004 |
| Date Type: |
Publication |
| Journal or Publication Title: |
Journal of Pharmacology and Experimental Therapeutics |
| Volume: |
309 |
| Number: |
1 |
| Page Range: |
64 - 70 |
| DOI or Unique Handle: |
10.1124/jpet.103.059477 |
| Schools and Programs: |
Dietrich School of Arts and Sciences > Chemistry |
| Refereed: |
Yes |
| ISSN: |
0022-3565 |
| MeSH Headings: |
CDC2 Protein Kinase--metabolism; Cell Division--drug effects; Cell Fractionation; Cell Line; Dicumarol--pharmacology; G2 Phase--drug effects; HT29 Cells; Humans; Microsomes--metabolism; Mitosis--drug effects; NAD(P)H Dehydrogenase (Quinone)--metabolism; NAD(P)H Dehydrogenase (Quinone)--physiology; Naphthoquinones--pharmacology; Phosphorylation; Quinolones--pharmacology; Quinones--pharmacology; Recombinant Proteins--metabolism; Tumor Cells, Cultured; cdc25 Phosphatases--antagonists & inhibitors |
| PubMed ID: |
14718602 |
| Date Deposited: |
30 Jan 2014 18:20 |
| Last Modified: |
12 Jun 2021 22:55 |
| URI: |
http://d-scholarship-dev.library.pitt.edu/id/eprint/20431 |
Metrics
Monthly Views for the past 3 years
Plum Analytics
Altmetric.com
Actions (login required)
 |
View Item |
![[feed]](/images/feed-icon-32x32.png){kind=icon}